About Us
SQ Innovation is a privately held Swiss biopharmaceutical company located in Zug, Switzerland, and Burlington, Massachusetts, United States.
Founded to develop and commercialize innovative, cost-effective therapies for subcutaneous delivery, the company aims to enable at-home treatment for conditions traditionally managed in hospitals. SQ Innovation has developed a novel drug-device combination for treating fluid overload in adult patients with chronic heart failure — a condition typically requiring intravenous administration of medications in a hospital setting. This product, Lasix® ONYU, was developed with consideration for patients, payors, healthcare providers, and environmental impact. Lasix® ONYU received Tentative Approval from the US Food and Drug Administration in October 2024. Lasix ONYU has not been approved for sale.
Our Mission
We develop and manufacture innovative, quality combination products that are safe and effective.
Our Quality Policy
We are committed to meeting customer expectations and regulatory requirements; to develop and manufacture innovative high quality combination products, and to continually improve our processes and products.